Condition: Pheochromocytoma and Paraganglioma (PPGL) · Pheochromocytoma Malignant · Pheochromocytoma, Metastatic · Sponsor: Cambridge University Hospitals NHS Foundation Trust
To investigate the impact of a medication called Belzutifan on the production and subsequent metabolism of adrenaline and noradrenaline collectively termed 'catecholamines'. The study aims to identify changes in the production and metabolism of catecholamines by measuring the substance which starts the chain of catecholamine metabolism called tyrosine in patients before, during and after 5 days of taking Belzutifan 120mg daily.
This description comes directly from the study's public registry record.
August Palma Senior Research Nurse - Endocrinology · 01223 217 848 · august.palma@nhs.net
Always discuss trial participation with your own doctor first.
| Cambridge University Hospitals NHS Foundation Trust | Cambridge, Cambridgeshire, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07680205